These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 8434965)

  • 41. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.
    Greimel ER; Bjelic-Radisic V; Pfisterer J; Hilpert F; Daghofer F; du Bois A;
    J Clin Oncol; 2006 Feb; 24(4):579-86. PubMed ID: 16446330
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Preventive effect of urinastatin on cisplatin-induced nephrotoxicity].
    Kobayashi H; Ishizuka H; Hirashima Y; Ohi H; Demukai H; Moniwa M; Maeda M; Kobayashi T; Terao T; Kawashima Y
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Dec; 41(12):1959-64. PubMed ID: 2592819
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with ten-year follow-up.
    Shapiro F; Schneider J; Markman M; Reichman BS; Venkatraman E; Barakat R; Almadrones L; Spriggs D
    Gynecol Oncol; 1997 Oct; 67(1):39-45. PubMed ID: 9345354
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Results of the combination of cisplatin, adriamycin and cyclophosphamide in the treatment of ovarian carcinoma.
    Russo A; Gebbia V; Palmeri S; Geraci P; Maneschi F; Guarnieri G; Carollo F; Leonardi V; Meli M; Gebbia N
    Eur J Gynaecol Oncol; 1993; 14(3):228-33. PubMed ID: 8508880
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Survival in ovarian cancer treated in a gynecological department of a central hospital].
    Dragsted NO; Nørgaard M; Bøsling KB
    Ugeskr Laeger; 1997 May; 159(20):3003-9. PubMed ID: 9190729
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
    Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
    Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Multi-institutional cooperative study on combination chemotherapy with THP, CDDP and 5-FU for squamous cell carcinoma of the head and neck].
    Urade M; Yanagisawa T; Kishimoto H; Yoshioka W; Teranobu O; Shigeta Y; Komori T; Shimada K; Ohnishi M; Tanaka Y; Kamiya Y; Akazawa N; Oko T; Takahashi N; Adachi R; Tanigaki S; Hirata Y; Yakushiji N; Kitamura R; Hashikawa N;
    Gan To Kagaku Ryoho; 2001 Jun; 28(6):789-95. PubMed ID: 11432346
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).
    Gebbia V; Galetta D; Lorusso V; Caruso M; Verderame F; Pezzella G; Borsellino N; Durini E; Valenza R; Agostara B; Colucci G;
    Lung Cancer; 2008 Sep; 61(3):369-77. PubMed ID: 18308419
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Evaluation of efficacy of treatment for 30 children with neuroblastoma].
    Sun XF; Liu DG; Su YS; Lin TY; Chen XQ; He YJ
    Ai Zheng; 2003 Dec; 22(12):1343-5. PubMed ID: 14693065
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study.
    Susumu N; Sagae S; Udagawa Y; Niwa K; Kuramoto H; Satoh S; Kudo R;
    Gynecol Oncol; 2008 Jan; 108(1):226-33. PubMed ID: 17996926
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Effects of cepharanthin on leukopenia and thrombocytopenia caused by CDDP-ACR-CPA therapy of ovarian cancer].
    Ushiki N; Jobo T; Shimoda T; Kuramoto H; Arai M
    Gan To Kagaku Ryoho; 1988 Sep; 15(9):2701-6. PubMed ID: 3415268
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Experiences with cisplatin (Platidiam) chemotherapy in secondary resistant ovarian carcinomas].
    Krafft W; Mechl Z; Behling H; Brückmann D; Preibsch W; Kademann J; Schirmer A
    Zentralbl Gynakol; 1984; 106(3):175-83. PubMed ID: 6538371
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Cisplatin and ovarian carcinoma--early detection of cisplatin-induced nephrotoxicity].
    Kobayashi H
    Nihon Sanka Fujinka Gakkai Zasshi; 1985 Jun; 37(6):888-96. PubMed ID: 4040542
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Augmentative effects of radiofrequency hyperthermia (RFH) combined with intraperitoneal (IP) administration of CDDP in ovarian cancer].
    Ino Y; Takizawa K; Isono T; Sato M; Yokoo I; Iguchi T; Takeda Y; Yokoyama M
    Gan To Kagaku Ryoho; 1988 Jun; 15(6):1887-91. PubMed ID: 3382241
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [The value of cis-diamminedichloroplatinum (cis-platinum) CDDP in the treatment of stage III and IV cancers of the ovary (author's transl)].
    Amiel JL; Droz JP; Tursz T; Ayed FB; Gastiaburu J; Rouesse J
    J Gynecol Obstet Biol Reprod (Paris); 1979; 8(1):65-6. PubMed ID: 469203
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [High-dose CDDP therapy using a balloon-occluded arterial infusion (BOAI) in recurrent ovarian cancer].
    Suzumori K; Yasui Y; Yagami Y; Mimura M; Banno T; Nakamura T
    Gan No Rinsho; 1988 Aug; 34(9):1107-14. PubMed ID: 3172517
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intermittent cisplatin therapy for stage-III ovarian cancer patients following clinical remission.
    Umesaki N; Tanaka T; Muso H; Kawamura N; Kanaoka Y; Honda K; Deguchi M; Ishiko O; Ogita S
    Gynecol Obstet Invest; 1999; 47(2):139-43. PubMed ID: 9949286
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Intracavitary microspheres incorporating cisplatinum in the treatment of malignant effusions--clinical trials].
    Hagiwara A; Takahashi T; Yamaguchi T; Taniguchi H; Iwamoto A; Yoneyama C; Ito M; Sasabe T; Lee M; Wada R
    Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 2):1575-8. PubMed ID: 2389951
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Effects of urinastatin against nephrotoxicity of cisplatinum].
    Arakawa A; Kato N; Asai H; Yasui Y; Suzumori K; Suzumori K; Yagami Y
    Gan To Kagaku Ryoho; 1990 Nov; 17(11):2229-34. PubMed ID: 2241187
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combination chemotherapy with nedaplatin and cyclophosphamide in human ovarian cancer model.
    Uchida N; Yoshida H; Yamada H; Wada T; Daikatsu K; Ikeuchi I; Maekawa R; Sugita K; Yoshioka T
    Jpn J Cancer Res; 1999 Aug; 90(8):887-94. PubMed ID: 10543262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.